VOYAGE phase 3: Dupilumab significantly reduced asthma exacerbations in children age 6-11
Pregnancy during COVID-19 lockdown: How the pandemic has affected new mothers
19 May 2021Is it normal aging or early signs of dementia?
19 May 2021VOYAGE phase 3: Dupilumab significantly reduced asthma exacerbations in children age 6-11
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.
